Evidence map›Paper›PMID 40774250›Full record

ArticleCell metabolism2025

HNF1A and A1CF coordinate a beta cell transcription-splicing axis that is disrupted in type 2 diabetes.

Edgar Bernardo, Matías Gonzalo De Vas, Diego Balboa, Mirabai Cuenca-Ardura, Sílvia Bonàs-Guarch, Mercè Planas-Fèlix, Fanny Mollandin, Miquel Torrens-Dinarès, Miguel Angel Maestro, Javier García-Hurtado and 12 more

Abstract read
In one paragraph

Article in Cell metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Cross-Study Meta-Analysis of Blood Transcriptomes in Type 2 Diabetes.International journal of molecular sciences · 2025
    Pooled it
  2. Review
  3. Review
  4. RNA splicing in health and disease.Molecular biomedicine · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Edgar BernardoCentre for Genomic Regulation, the Barcelona Institute of Science and Technology, Barcelona, Spain; Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
Matías Gonzalo De VasSection of Genetics and Genomics, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Diego BalboaCentre for Genomic Regulation, the Barcelona Institute of Science and Technology, Barcelona, Spain; Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
Mirabai Cuenca-ArduraCentre for Genomic Regulation, the Barcelona Institute of Science and Technology, Barcelona, Spain; Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
Sílvia Bonàs-GuarchCentre for Genomic Regulation, the Barcelona Institute of Science and Technology, Barcelona, Spain; Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain; Section of Genetics and Genomics, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Mercè Planas-FèlixCentre for Genomic Regulation, the Barcelona Institute of Science and Technology, Barcelona, Spain; Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
Fanny MollandinCentre for Genomic Regulation, the Barcelona Institute of Science and Technology, Barcelona, Spain; Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
Miquel Torrens-DinarèsCentre for Genomic Regulation, the Barcelona Institute of Science and Technology, Barcelona, Spain; Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
Miguel Angel MaestroCentre for Genomic Regulation, the Barcelona Institute of Science and Technology, Barcelona, Spain; Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
Javier García-HurtadoCentre for Genomic Regulation, the Barcelona Institute of Science and Technology, Barcelona, Spain; Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
Sonia MoratinosCentre for Genomic Regulation, the Barcelona Institute of Science and Technology, Barcelona, Spain; Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
Philippe RavassardParis Brain Institute, Sorbonne Université, Inserm U1127, CNRS UMR 7225, Paris, France.
Haiqiang DouDepartment of Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Holger HeynCentro Nacional de Análisis Genómico (CNAG), Barcelona, Spain.
Alexander van OudenaardenOncode Institute, Utrecht, the Netherlands; Hubrecht Institute-KNAW, Utrecht, the Netherlands; University Medical Center Utrecht, Utrecht, the Netherlands.
Nathalie GroenHubrecht Institute, Royal Netherlands Academy of Arts and Sciences, and University Medical Center, Utrecht, the Netherlands; Department of Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Eelco de KoningHubrecht Institute, Royal Netherlands Academy of Arts and Sciences, and University Medical Center, Utrecht, the Netherlands; Department of Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Christian ConradBerlin Institute of Health at Charité - Universitätsmedizin Berlin, Center of Digital Health, Berlin, Germany.
Roland EilsBerlin Institute of Health at Charité - Universitätsmedizin Berlin, Center of Digital Health, Berlin, Germany; Health Data Science Unit, Heidelberg University Hospital and BioQuant, Heidelberg, Germany.
Santiago VerniaMRC Laboratory of Medical Sciences (LMS), London, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College, London, UK.
Patrik RorsmanDepartment of Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK.
Jorge FerrerCentre for Genomic Regulation, the Barcelona Institute of Science and Technology, Barcelona, Spain; Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain; Section of Genetics and Genomics, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK. Electronic address: jorge.ferrer@crg.eu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes (T2D) is a devastating chronic disease marked by pancreatic β cell dysfunction and insulin resistance, whose pathophysiology remains poorly understood. HNF1A, which encodes transcription factor hepatocyte nuclear factor-1 alpha, is the most commonly mutated gene in Mendelian diabetes. HNF1A also carries loss- or gain-of-function coding variants that respectively predispose to or protect against polygenic T2D. The mechanisms underlying HNF1A-deficient diabetes, however, are still unclear. We now demonstrate that diabetes arises from β cell-autonomous defects and identify direct β cell genomic targets of HNF1A. This uncovered a regulatory axis where HNF1A controls transcription of A1CF, which orchestrates an RNA splicing program encompassing genes that regulate β cell function. This HNF1A-A1CF transcription-splicing axis is suppressed in β cells from T2D individuals, while genetic variants reducing pancreatic islet A1CF are associated with increased glycemia and T2D susceptibility. Our findings, therefore, identify a linear hierarchy that coordinates β cell-specific transcription and splicing programs and link this pathway to T2D pathogenesis.

Indexed as

Diabetes Mellitus, Type 2Hepatocyte Nuclear Factor 1-alphaInsulin-Secreting CellsRNA SplicingTranscription, GeneticAnimalsHumansMaleMiceMice, Inbred C57BLHepatocyte Nuclear Factor 1-alphaHNF1A protein, humangene regulatory networksgenetics of diabetesgene transcriptionHNF1AHNF1 homeobox Ahuman embryonic stem cell-derived isletshuman geneticsMODY-3pancreatic beta cellspancreatic isletsRNA splicingsplicing factor networkstype 2 diabetes

Identifiers

PMID40774250
PMCPMC12714141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.